gimli

GKSL stock AI analysis

GKSL Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers

GUJARAT KIDNEY N SUP SP L is a small-cap stock in Healthcare. This Gimli page shows the latest available GKSL price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.

Analyze with AI Open interactive GKSL stock page

Price

₹181.25

1W return

+4.64%

1M return

+18.11%

3M return

+41.38%

6M return

+72.64%

1Y return

n/a

Market cap

₹1,429.03 cr

76.58

5.61

ROE

+12.67%

ROCE

+13.36%

RSI

77.14

Turnover

₹4.95 cr

Why it can matter in screens

Momentum: GKSL is above 50DMA, below 200DMA; RSI is 77.14.
Returns: 1D +1.93%, 1W +4.64%, 1M +18.11%, 3M +41.38%, 1Y n/a.
Trend levels: 52W high ₹186.00, 52W low ₹122.24, off high -2.55%.
Liquidity: latest turnover is ₹4.95 cr; volume vs 20D is +0.46%.
Valuation/profitability: PE 76.58, PB 5.61, ROE +12.67%, ROCE +13.36%.
Growth: 3Y sales CAGR -1.49%, 3Y profit CAGR +32.65%.

Quick Answers

What is the latest GKSL stock price?

The latest stored price for GKSL is Rs 181.25 as of 2026-09-18.

Is GKSL above its 50DMA and 200DMA?

GKSL is above 50DMA, below 200DMA. The latest 50DMA is 147.03 and the latest 200DMA is n/a.

What are GKSL PE, ROE and ROCE?

GKSL has PE 76.58, ROE +12.67%, and ROCE +13.36% in Gimli's latest available snapshot.

How has GKSL performed recently?

GKSL has returned +18.11% over 1 month, +41.38% over 3 months, and n/a over 12 months in the latest stored data.

Is this stock page investment advice?

No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.

Financials and Ownership

Quarterly income statement

Period	Revenue	EBITDA	PAT	EPS
2026-03-31	30.58 cr	7.01 cr	5.04 cr	0.81
2025-12-31	23.25 cr	6.96 cr	2.94 cr	0.52
2025-09-30	13.02 cr	5.21 cr	2.88 cr	0.47
2025-06-30	31.09 cr	13.66 cr	7.80 cr	0.99
2025-03-31	9.78 cr	2.67 cr	1.28 cr	0.16
2024-12-31	11.79 cr	4.65 cr	2.50 cr	0.32

Annual income statement

Year	Revenue	EBITDA	PAT	EPS
2026-03-31	82.01 cr	27.81 cr	15.50 cr	2.49
2025-03-31	40.24 cr	16.70 cr	9.41 cr	1.19
2024-03-31	103.44 cr	22.03 cr	9.68 cr	1.23
2023-03-31	85.79 cr	17.93 cr	6.64 cr	0.84

Balance sheet

Period	Assets	Cash	Debt	Equity
2026-03-31	297.64 cr	13.28 cr	29.11 cr	254.74 cr
2025-03-31	91.29 cr	4.58 cr	22.77 cr	39.83 cr
2024-03-31	65.40 cr	3.90 cr	27.34 cr	22.85 cr
2023-03-31	63.86 cr	1.90 cr	23.20 cr	22.30 cr

Cash flow

Period	OCF	FCF	Cash change
2026-03-31	-3.86 cr	-157.28 cr	n/a
2025-03-31	13.61 cr	-4.64 cr	n/a
2024-03-31	1.21 cr	1.21 cr	n/a
2023-03-31	0.00 cr	0.00 cr	n/a

Shareholding Trend

Period	Promoter	FII/FPI	DII	MF	Retail	Pledge
2026-06-30	+71.45%	+4.88%	+0.56%	+0.00%	+23.10%	+0.00%
2026-03-31	+71.45%	+4.88%	+0.56%	+0.00%	+23.10%	+0.00%
2025-12-31	+71.45%	+10.47%	+1.67%	+0.00%	+16.40%	+0.00%
2025-12-29	+71.45%	+13.09%	+7.84%	+0.00%	+7.62%	+0.00%

Industry Peers

Symbol	Name	Mcap	PE	ROE	1Y
SUNPHARMA	SUN PHARMACEUTICAL IND L	440,829.82 cr	36.388220	+15.50%	+11.45%
DIVISLAB	DIVI S LABORATORIES LTD	248,876.81 cr	85.407280	+18.37%	+53.39%
TORNTPHARM	TORRENT PHARMACEUTICALS L	163,807.57 cr	75.106636	+17.33%	+35.67%
APOLLOHOSP	APOLLO HOSPITALS ENTER. L	128,608.22 cr	65.670049	+21.03%	+13.94%
ZYDUSLIFE	ZYDUS LIFESCIENCES LTD	116,723.14 cr	26.011308	+16.04%	+10.70%
CIPLA	CIPLA LTD	112,647.78 cr	33.401961	+10.25%	-11.64%
LAURUSLABS	LAURUS LABS LIMITED	105,487.98 cr	96.587446	+21.77%	+111.64%
MAXHEALTH	MAX HEALTHCARE INS LTD	102,122.47 cr	70.799892	+14.33%	-10.58%

Try these prompts

Analyze GUJARAT KIDNEY N SUP SP L with valuation, momentum and industry peers
Compare GKSL with other Healthcare stocks
Show small-cap stocks in Healthcare above 50DMA with positive 1M return
Find Healthcare stocks with improving momentum and reasonable valuation

Related screen ideas

Data snapshot: 2026-09-18. Not investment advice.